Co-Authors
This is a "connection" page, showing publications co-authored by Katie Doores and Gaia Nebbia.
Connection Strength
0.575
-
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020 12; 5(12):1598-1607.
Score: 0.227
-
Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. Clin Microbiol Infect. 2022 Jan; 28(1):93-100.
Score: 0.060
-
Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. Lancet Microbe. 2021 Sep; 2(9):e461-e471.
Score: 0.060
-
Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. PLoS One. 2021; 16(4):e0249791.
Score: 0.059
-
Translational Research in the Time of COVID-19-Dissolving Boundaries. PLoS Pathog. 2020 09; 16(9):e1008898.
Score: 0.057
-
Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathog. 2020 09; 16(9):e1008817.
Score: 0.057
-
Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome. Analyst. 2020 Aug 21; 145(16):5638-5646.
Score: 0.056